Nachrichten zur Regeneron Pharmaceuticals Inc. Aktie

Regeneron Provides Update on Biologics License Application for Linvoseltamab

TARRYTOWN, N.Y., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S.…

[Latest] Global Genetic Engineering Market Size/Share Worth USD 2,917.2 Million by 2033 at a 6.74% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Regeneron Pharmaceuticals: Neues Kursziel

London (www.aktiencheck.de) - Rating-Update: Die Analysten von Barclays stufen die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535, Ticker-Symbol: RGO,…

Is Regeneron Pharmaceuticals Due for a Stock Split?

Would a stock split help lead Regeneron Pharmaceuticals shares higher?…

Is Regeneron Pharmaceuticals Due for a Stock Split? @themotleyfool #stocks $REGN

Would a stock split help lead Regeneron Pharmaceuticals shares higher?…

Defensive Sectors Breakout: 3 Stocks to Buy Now for Protection

AvalonBay Communities, Regeneron Pharmaceuticals and Public Service Enterprise Group are all rallying as investors rotate into defensive sectors…

Top Analyst Reports for Goldman Sachs, RTX & Regeneron

Todays Research Daily features new research reports on 16 major stocks, including The Goldman Sachs Group, Inc. (GS), RTX Corporation…

Regeneron Pharmaceuticals: Bullische Sichtweise unterstützt - Aktienanalyse

Minneapolis (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von Piper Sandler: Die Analysten von Piper Sandler erhöhen in einer aktuellen Aktienanalyse ihr Kursziel für…

Regeneron Pharmaceuticals: Kurszielanhebung

London (www.aktiencheck.de) - Rating-Update: Barclays stuft die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535, Ticker-Symbol: RGO, NASDAQ-Symbol: REGN) weiterhin…

Regeneron Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

13:27: Sanofi: gemeinsame Zulassung mit Regeneron Pharmaceuticals für Blockbuster Dupixent

Fortschritte bei Lungenerkrankungen könnten die Sanofi-Aktie (SAN) beflügeln!Jetzt Swingtrade starten?Sanofi (SAN) – FR0000120578RückblickMit einem Kursverlust von knapp 2.5 Prozent in…

Sanofi erhält EU-Zulassung für Dupixent als COPD-Therapie

DJ Sanofi erhält EU-Zulassung für Dupixent als COPD-Therapie Von Adria Calatayud PARIS (Dow Jones)--Sanofi und Regeneron Pharmaceuticals haben von der…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024

TARRYTOWN, N.Y., June 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will…

Oncology Stocks: 8 Biggest NASDAQ Companies in 2024

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.Coming in only after cardiovascular disease, cancer…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Regeneron Pharmaceuticals: Ein potenzieller Aktiensplit könnte für positive Impulse sorgen - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Regeneron Pharmaceuticals Inc.…

Regeneron Pharmaceuticals: "overweight"

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Morgan Stanley stufen die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535,…

Regeneron Pharmaceuticals: Neues Kursziel

San Francisco (www.aktiencheck.de) - Rating-Update: Die Analysten von Wells Fargo Advisors stufen die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN:…

Regeneron Pharmaceuticals, Inc. (REGN) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)

…

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avangrid, Inc. (NYSE - AGR), SilverBow Resources, Inc. (NYSE - SBOW), Reneo Pharmaceuticals, Inc. (Nasdaq - RPHM), Perficient, Inc. (Nasdaq - PRFT)

BALA CYNWYD, Pa., June 07, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.…

Regeneron Pharmaceuticals, Inc. (REGN) Management presents at Jefferies 2024 Global Healthcare Conference (Transcript)

…

Regeneron Pharmaceuticals: RBC Capital erhöht Kursziel - Dupixent im Fokus - Aktienanalyse

Toronto (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von RBC Capital Markets: Die kanadische Bank RBC Capital Markets stuft die Aktie von Regeneron Pharmaceuticals…

Minimale Kursveränderung bei Regeneron Pharmaceuticals-Aktie (893,3290 €)

CODE Zuletzt zahlten Investoren für die Aktie 968,86 US-Dollar. Wenig getan hat sich heute bislang beim Kurs von Regeneron Pharmaceuticals.…

Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today…

5 Biggest Pharmaceutical ETFs in 2024

The global pharmaceutical market reached a total value of US$1.6 trillion in 2023, according to Statista, up significantly from the…

Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm

NEW YORK, May 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)

…

Regeneron Pharmaceuticals: Evercore ISI nimmt Coverage auf - Aktienanalyse

New York (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von Evercore ISI: Die Analysten von Evercore ISI nehmen die Coverage für die Aktie von…

Reneo Pharmaceuticals and OnKure Announce Proposed Merger

Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology…

FDA prüft Antrag von Regeneron und Sanofi für Dupixent vorrangig

Von Colin Kellaher NEW YORK (Dow Jones)--Die US-Gesundheitsbehörde FDA prüft eine Zulassungserweiterung für das entzündungshemmende Blockbuster-Medikament Dupixent von Regeneron…

Regeneron Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation

…

Regeneron misses profit estimates on weaker Eylea and Dupixent sales

U.S. drugmaker Regeneron Pharmaceuticals Inc missed Wall Street estimates for first-quarter profit on Thursday due to softer sales of its…

Regeneron Pharmaceuticals: Kursziel gesteigert

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von TD Cowen stufen die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535,…

The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power

Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power are part of the Zacks top Analyst Blog.…

Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks

Todays Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Regeneron Pharmaceuticals, Inc. (REGN) and…

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential…

Regeneron Pharmaceuticals: Kursziel angehoben

Charlotte (www.aktiencheck.de) - Rating-Update: Geoff Meacham, Analyst von BofA Securities, stuft die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535,…

Regeneron Pharmaceuticals: Kaufgelegenheit in der Underperformance - Aktienanalyse

Toronto (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von RBC Capital Markets: Die kanadische Bank RBC Capital Markets stuft die Aktie von Regeneron Pharmaceuticals…

Regeneron Pharma falls after US government alleges fraud

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) faced a blow in pre-market trading after being hit with fraud allegations from the US Justice…

Biotech Stocks: 5 Biggest Companies in 2024

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in…

How to Invest in Biotechnology (Updated 2024)

Investors interested in the life science sector are well aware of the importance of biotechnology.From finding cures for diseases to…

Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused…

Food Allergy Treatment Drug Market to Register Immense Growth by 2032, Assesses DelveInsight | Key Companies - Vedanta Biosciences, Novartis, Alladapt Immunotherapeutics, Regeneron Pharmaceuticals, Genentech, Parexel

The overall dynamics of the food allergy market are anticipated to change in the coming years owing to the expected…

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)

…

dpa-AFX ProFeed